摘要
目的探讨阿托伐他汀联合尼莫地平治疗血管性认知功能障碍的疗效及对患者日常生活活动能力的影响。方法选取医院2016年1月至2017年10月收治的血管性认知功能障碍患者90例,按随机数字表法分为对照组和观察组,各45例。对照组患者在常规药物治疗的基础上给予尼莫地平治疗,观察组患者在对照组患者治疗基础上加服阿托伐他汀,两组均连续治疗12周。结果观察组总有效率为93.33%,明显高于对照组的75.56%(P<0.05);两组患者简易智能精神状态检查量表(MMSE)各项评分均较治疗前改善,且观察组均明显高于对照组(P<0.05);两组患者日常生活活动能力(ADL)评分均较治疗前提高,且观察组提高更明显(P<0.05);对照组患者出现胃肠道反应、皮疹各1例,观察组患者出现皮疹、头晕各1例,胃肠道反应2例;两组患者药品不良反应发生率相当(4.44%比8.89%,P>0.05)。结论阿托伐他汀联合尼莫地平治疗血管性认知功能障碍可明显提高疗效,改善认知功能,提高日常生活活动能力,且不良反应少,值得推广。
Objective To investigate the effect of atorvastatin combined with nimodipine on activities of daily living（ADL） in patients with vascular cognitive impairment.Methods Totally 90 patients with vascular cognitive impairment admitted to our hospital from January 2016 to October 2017 were selected and randomly divided into the control group and the observation group,45 cases in each group.The control group was treated with nimodipine on the basis of routine drug treatment,on this basis,the observation group was treated with atorvastatin.The two groups were treated continuously for 12 weeks.Results The total effective rate of the observation group was 93.33%,which was significantly higher than 75.56% of the control group（P〈0.05）.After treatment,the scores of mini-mental state examination（MMSE） in the two groups were improved compared with those before treatment,and the scores in the observation group were higher than those of the control group（P〈0.05）.The ADL scores in the two groups were higher than those before treatment,and the improvement in the observation group was more significant（P〈0.05）.There were 1 case of gastrointestinal reaction and 1 case of skin rash in the control group,and there were 1 case of skin rash,1 case of dizziness and 2 cases of gastric bowel reactions in the observation group,there was no significant difference in the incidence rate of adverse drug reactions between the two groups（4.44% vs.8.89%,P〉0.05）.Conclusion Atorvastatin combined with nimodipine in the treatment of patients with vascular cognitive impairment can significantly improve the therapeutic effect,cognitive function and ADL with fewer adverse reactions,which is worthy of clinical promotion.
作者
刘卫花
刘德浪
黄宏敏
赵光峰
Liu Weihua;Liu Delang;Huang Hongmin;Zhao Guangfeng(Department of Encephalopathy,Chinese Medicine Hospital of Hainan Province,Haikou,Hainan,China 57020)
出处
《中国药业》
CAS
2018年第12期25-27,共3页
China Pharmaceuticals
基金
海南省自然科学基金[813236]
